Page 151 - 南京医科大学自然版

第46卷第6期 汤依然，李 迎，厉廷有. 基于功能蛋白设计靶向多肽及小分子化合物：5个神经系统疾
2026年6月 病候选药物的设计策略［J］. 南京医科大学学报（自然科学版），2026，46（6）：927-934 ·933 ·

Author’s Contributions： or neurotrophic compound［J］. Neurobiol Aging，2014，
TANG Yiran was responsible for literature collection， 35（9）：2134-2146

analysis and first draft writing；LI Ying was responsible for ［12］KAZIM S F，IQBAL K. Neurotrophic factor small⁃mole⁃
content and format proofreading；LI Tingyou was responsible for cule mimetics mediated neuroregeneration and synaptic
funding support and manuscript review. repair：emerging therapeutic modality for Alzheimer’s
［参考文献］ disease［J］. Mol Neurodegener，2016，11（1）：50
［13］ASHINA M，PHUL R，KHODAIE M，et al. A monoclonal
［1］ SIMS E K，CARR A L J，ORAM R A，et al. 100 years of
antibody to PACAP for migraine prevention［J］. N Engl J
insulin：celebrating the past，present and future of diabe⁃
Med，2024，391（9）：800-809
tes therapy［J］. Nat Med，2021，27（7）：1154-1164
［14］XU W Q，KEITH A M，YE W J，et al. Design of peptide⁃
［2］ MUTTENTHALER M，KING G F，ADAMS D J，et al.
based PAC1 antagonists combining molecular dynamics
Trends in peptide drug discovery［J］. Nat Rev Drug Dis⁃
simulations and a biologically relevant cell⁃based assay［J］.
cov，2021，20（4）：309-325
Biochem Pharmacol，2025，242：117300
［3］ HAN Z Y，SHEN Z K，PEI J Y，et al. Transformation of
［15］ ZHANG L，ZHOU Y J，YANG L，et al. PACAP6⁃38
peptides to small molecules in medicinal chemistry：chal⁃
improves nitroglycerin ⁃ induced central sensitization by
lenges and opportunities［J］. Acta Pharm Sin B，2024，14
modulating synaptic plasticity at the trigeminal nucleus
（10）：4243-4265
caudalis in a male rat model of chronic migraine［J］. J
［4］ LI Q，MA Z B，QIN S H，et al. Virtual screening⁃based
Headache Pain，2023，24（1）：66
drug development for the treatment of nervous system
［16］TAKASAKI I，WATANABE A，YOKAI M，et al. In silico
diseases［J］. Curr Neuropharmacol，2023，21（12）：2447-
screening identified novel small⁃molecule antagonists of
2464 PAC1 receptor［J］. J Pharmacol Exp Ther，2018，365（1）：
［5］ RAWAL S U，PATEL B M，PATEL M M. New drug delivery
1-8
systems developed for brain targeting［J］. Drugs，2022，82
［17］ LU J，PIPER S J，ZHAO P，et al. Targeting VIP and
（7）：749-792
PACAP receptor signaling：new insights into designing
［6］ DA COSTA A，FRANCO⁃DUARTE R，MACHADO R，et
drugs for the PACAP subfamily of receptors［J］. Int J Mol
al. Uncovering the promiscuous activity of IL⁃6 proteins：
Sci，2022，23（15）：8069
a multi⁃dimensional analysis of phylogeny，classification
［18］ TASMA Z，REES T A，GUO S，et al. Pharmacology of
and residue conservation［J］. Protein Sci，2022，31（11）：
PACAP and VIP receptors in the spinal cord highlights
e4469 the importance of the PAC1 receptor［J］. British J Phar⁃
［7］ ZHANG X，YANG C，ZHANG C L，et al. Functional optic
macology，2024，181（15）：2655-2675
tract rewiring via subtype ⁃ and target ⁃ specific axonal ［19］SHINTANI Y，HAYATA⁃TAKANO A，YAMANO Y，et al.
regeneration and presynaptic activity enhancement［J］. Small ⁃ molecule non ⁃ peptide antagonists of the PACAP
Nat Commun，2025，16：2174 receptor attenuate acute restraint stress⁃induced anxiety⁃
［8］ CHOHAN M O，LI B，BLANCHARD J，et al. Enhance⁃ like behaviors in mice［J］. Biochem Biophys Res Commun，
ment of dentate gyrus neurogenesis，dendritic and synap⁃ 2022，631：146-151
tic plasticity and memory by a neurotrophic peptide［J］. ［20］SHINTANI Y，HAYATA⁃TAKANO A，TAKASAKI I，et
Neurobiol Aging，2011，32（8）：1420-1434 al. Rapid and long⁃lasting antidepressant⁃like effects of
［9］ BLANCHARD J，CHOHAN M O，LI B，et al. Beneficial the pituitary adenylate cyclase ⁃ activating polypeptide
effect of a CNTF tetrapeptide on adult hippocampal receptor antagonist PA ⁃ 915 in chronic stress mouse
neurogenesis，neuronal plasticity，and spatial memory in models［J］. Mol Psychiatry，2026，31（2）：1014-1026
mice［J］. J Alzheimers Dis，2010，21（4）：1185-1195 ［21］UNNISA A，GREIG N H，KAMAL M A. Inhibition of
［10］MOTTOLESE N，LOI M，TRAZZI S，et al. Effects of a caspase 3 and caspase 9 mediated apoptosis：a multimodal
ciliary neurotrophic factor（CNTF ） small ⁃ molecule therapeutic target in traumatic brain injury［J］. Curr
peptide mimetic in an in vitro and in vitro model of Neuropharmacol，2023，21（4）：1001-1012
CDKL5 deficiency disorder［J］. J Neurodev Disord，2024， ［22］ DHANI S，ZHAO Y，ZHIVOTOVSKY B. A long way to
16（1）：65 go：caspase inhibitors in clinical use［J］. Cell Death Dis，
［11］BOLOGNIN S，BUFFELLI M，PUOLIVÄLI J，et al. Rescue 2021，12（10）：949
of cognitive⁃aging by administration of a neurogenic and/ ［23］XIA Y，HUANG P，QIAN Y Y，et al. PARP inhibitors